Current through Register Vol. 24-18, September 15, 2024
(1)
Purpose. For the purposes of this section, sleep studies include
polysomnogra-phy (PSG), unattended home sleep test (HST), and multiple sleep
latency testing (MSLT). The medicaid agency covers attended, full-channel, PSG,
MSLT, and unattended HSTs when:
(a) Ordered by
the client's physician;
(b)
Performed by an agency-designated center of excellence (COE) that is an
independent diagnostic testing facility, sleep laboratory, or outpatient
hospital; and
(c) Results are used
to:
(i) Establish a diagnosis of narcolepsy
or sleep apnea; or
(ii) Evaluate a
client's response to therapy, such as continuous positive airway pressure
(CPAP).
(2)
Definitions. The following definitions, those found in chapter 182-500 WAC, and
definitions found in other sections of this chapter, apply to this section:
(a) "American Academy of Sleep Medicine" or
"AASM" - The only professional society dedicated exclusively to the medical
subspecialty of sleep medicine. AASM sets standards and promotes excellence in
health care, education, and research. Members specialize in studying,
diagnosing, and treating disorders of sleep and daytime alertness such as
insomnia, narcolepsy, and obstructive sleep apnea.
(b) "Continuous positive airway pressure" or
"CPAP" -See WAC
182-552-0005.
(c) "Core provider agreement" or "CPA" - The
basic contract the agency holds with providers serving medical assistance
clients.
(d) "Multiple sleep
latency test" or "MSLT" - A sleep disorder diagnostic tool used to measure the
time elapsed from the start of a daytime nap period to the first signs of
sleep, called sleep latency. The MSLT is used extensively to test for
narcolepsy, to distinguish between physical tiredness and true excessive
daytime sleepiness, or to assess whether treatments for breathing disorders are
working.
(e) "Obstructive sleep
apnea" or "OSA" - See WAC
182-552-0005.
(f) "Polysomnogram" - The test results from a
polysom-nography.
(g)
"Polysomnography" - A multiparametric test that electronically transmits and
records specific physical activities while a person sleeps. The recordings
become data that are analyzed by a qualified sleep specialist to determine
whether or not a person has a sleep disorder.
(h) "PSG" - The abbreviation for both
"polysomnogra-phy" and "polysomnogram."
(i) "Registered polysomnographic
technologist" or "RPSGT" - A sleep technologist credentialed by the board of
registered polysomnographic technologists to assist sleep specialists in the
clinical assessment, physiological monitoring and testing, diagnosis,
management, and prevention of sleep-related disorders with the use of various
diagnostic and therapeutic tools. These tools include, but are not limited to,
polysomnograph, positive airway pressure devices, oximeter, capnograph,
actigraph, nocturnal oxygen, screening devices, and questionnaires. To become
certified as a registered poly-somnographic technologist, a sleep technologist
must have the necessary clinical experience, hold CPR certification or its
equivalent, adhere to the board of registered polysomno-graphic technologists
standards of conduct, and pass the registered polysomnographic technologist
examination for poly-somnographic technologists.
(3) Client eligibility. Clients in the
following agency programs are eligible to receive sleep studies as described in
this section:
(a) Categorically needy
(CN);
(b) Apple health for kids and
other children's medical assistance programs as defined in WAC
182-505-0210;
(c) Medical care services as described in WAC
182-508-0005
(within Washington state or border areas only); and
(d) Medically needy (MN) only when the client
is either:
(i) Twenty years of age or younger
and referred by a screening provider under the early and periodic screening,
diagnosis, and treatment program as described in chapter 182-534 WAC;
or
(ii) Receiving home health care
services as described in chapter 182-551 WAC, subchapter II.
(4) Provider
requirements. To be paid for providing sleep studies as described in this
section to eligible clients, the facility must:
(a) Be a sleep study COE. Refer to subsection
(5) of this section for information on becoming an agency-approved sleep study
COE;
(b) Be currently accredited by
AASM and continuously meet the accreditation standards of AASM;
(c) Have at least one physician on staff who
is board certified in sleep medicine; and
(d) Have at least one registered
polysomnographic technologist (RPSGT) in the sleep lab when studies are being
performed.
(5)
Documentation.
(a) To become an
agency-approved COE, a sleep center must send the following documentation to
the Health Care Authority, c/o Provider Enrollment, P.O. Box 45510, Olym-pia,
WA 98504-5510:
(i) A completed CPA;
and
(ii) A copy of the sleep
center's current accreditation certificate by AASM.
(b) Facilities accredited by the AASM must be
in compliance with all accreditation standards at the time of application and
throughout the accreditation period.
(c) Sleep centers must request
reaccreditation from AASM in time to avoid expiration of COE status with the
agency.
(d) At least one physician
on staff at the sleep center must be board certified in sleep medicine. If the
only physician on staff who is board certified in sleep medicine resigns, the
sleep center must ensure another physician on staff at the sleep center obtains
board certification or another board-certified physician is hired. The sleep
center must then send provider enrollment a copy of the physician's board
certification.
(e) If a certified
medical director leaves a COE, the COE status does not transfer with the
medical director to another sleep center.
(f) The COE must maintain a record of the
physician's order for the sleep study.
(6) Coverage.
(a) The agency pays for only medically
necessary sleep studies. The need for the sleep study must be confirmed by
medical evidence (e.g., physician examination and laboratory tests).
(b) For clients age twenty-one and older, the
agency covers:
(i) An unattended home sleep
test (HST) as follows:
(A) Using one of the
following HST devices:
(I) Type II home sleep
monitoring device;
(II) Type III
home sleep monitoring device; or
(III) Type IV home sleep monitoring device
that measures at least three channels.
(B) To confirm obstructive sleep apnea (OSA)
in an individual with signs or symptoms consistent with OSA (e.g., loud
snoring, awakening with gasping or choking, excessive daytime sleepiness,
observed cessation of breathing during sleep, etc.).
(ii) Full-night, in-laboratory PSG for either
of the following:
(A) Confirmation of
obstructive sleep apnea (OSA) in an individual with signs or symptoms
consistent with OSA (e.g., loud snoring, awakening with gasping or choking,
excessive daytime sleepiness, observed cessation of breathing during sleep,
etc.); or
(B) Titration of positive
airway pressure therapy when initial PSG confirms the diagnosis of OSA, and
positive airway pressure is ordered; or
(iii) Split-night, in-laboratory PSG in which
the initial diagnostic portion of the PSG is followed by positive airway
pressure titration when the PSG meets either of the following criteria:
(A) The apnea-hypopnea index (AHI) or
respiratory disturbance index (RDI) is greater than or equal to fifteen events
per hour; or
(B) The AHI or RDI is
greater than or equal to five and less than or equal to fourteen events per
hour with documentation of either of the following:
(I) Excessive daytime sleepiness, impaired
cognition, mood disorders, or insomnia; or
(II) Hypertension, ischemic heart disease, or
history of stroke.
(c) The agency considers any of the following
indications medically necessary for clients age twenty and younger:
(i) OSA suspected based on clinical
assessment;
(ii) Obesity, Trisomy
21, craniofacial abnormalities, neuromuscular disorders, sickle cell disease,
or mucopoly-saccharidosis (MPS), prior to adenotonsillectomy in a
child;
(iii) Residual symptoms of
OSA following mild preoper-ative OSA;
(iv) Residual symptoms of OSA in a child with
preoper-ative evidence of moderate to severe OSA, obesity, craniofa-cial
anomalies that obstruct the upper airway, or neurologic disorder following
adenotonsillectomy;
(v) Titration
of positive airway pressure in a child with OSA;
(vi) Suspected congenital central alveolar
hypoventila-tion syndrome or sleep related hypoventilation due to
neuro-muscular disorder or chest wall deformities;
(vii) Primary apnea of infancy;
(viii) Evidence of a sleep-related breathing
disorder in an infant who has experienced an apparent life threatening
event;
(ix) Child being considered
for adenotonsillectomy to treat OSA; or
(x) Clinical suspicion of an accompanying
sleep-related breathing disorder in a child with chronic asthma, cystic
fibrosis, pulmonary hypertension, bronchopulmonary dys-plasia, or chest wall
abnormality.
(7) Noncoverage. The agency does not cover
sleep studies:
(a) When documentation for a
repeat study does not indicate medical necessity (e.g., no new clinical
documentation indicating the need for a repeat study); or
(b) For the following indications, except
when an underlying physiology exists (e.g., loud snoring, awakening with
gasping or choking, excessive daytime sleepiness, observed cessation of
breathing during sleep, etc.):
(i) Chronic
insomnia; and
(ii)
Snoring.
11-14-075, recodified as §182-531-1500, filed 6/30/11,
effective 7/1/11. Statutory Authority:
RCW
74.08.090. 10-19-057, § 388-531-1500,
filed 9/14/10, effective 10/15/10. Statutory Authority:
RCW
74.08.090,
74.09.520. 01-01-012, §
388-531-1500, filed 12/6/00, effective
1/6/01.